Document is current
Any future updates will be listed below
-
Authors
Santos, Gabriel Nascimento De Souza
DeJohn, Celia https://orcid.org/0000-0002-4260-5847
Hess, Suzanne M
Zsiros, Emese https://orcid.org/0000-0003-0142-7375
McGray, A J Robert https://orcid.org/0000-0002-7145-8444
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03158935 at ClinicalTrials.govnct03017131 at ClinicalTrials.govDocuments that mention this clinical trial
Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms
https://doi.org/10.1136/jitc-2025-013285
nct02876510 at ClinicalTrials.govDocuments that mention this clinical trial
Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms
https://doi.org/10.1136/jitc-2025-013285
Immunological configuration of ovarian carcinoma: features and impact on disease outcome
https://doi.org/10.1136/jitc-2021-002873
nct05862324 at ClinicalTrials.govDocuments that mention this clinical trial
Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms
https://doi.org/10.1136/jitc-2025-013285
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
293 Resultsof the first-in-human clinical trial with personalized multi-target adoptive cell therapy (ACTolog IMA101)
https://doi.org/10.1136/jitc-2020-sitc2020.0293
nct03016377 at ClinicalTrials.govDocuments that mention this clinical trial
Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms
https://doi.org/10.1136/jitc-2025-013285
738 A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors
https://doi.org/10.1136/jitc-2023-sitc2023.0738
First-in-human phase 1/2 trial evaluating TAC01-CLDN18.2 autologous T cells in CLDN18.2-positive solid tumors.
https://doi.org/10.1200/jco.2024.42.3_suppl.tps419
1472 A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2+ advanced solid tumors
https://doi.org/10.1136/jitc-2024-sitc2024.1472
nct03054298 at ClinicalTrials.govDocuments that mention this clinical trial
Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms
https://doi.org/10.1136/jitc-2025-013285
nct03907527 at ClinicalTrials.govDocuments that mention this clinical trial
Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms
https://doi.org/10.1136/jitc-2025-013285
Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model
https://doi.org/10.1136/jitc-2022-006509
nct01174121 at ClinicalTrials.govDocuments that mention this clinical trial
Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms
https://doi.org/10.1136/jitc-2025-013285
Phase 1/1b study of PRGN-3005 autologous UltraCAR-T cells manufactured overnight for infusion next day to advanced stage platinum resistant ovarian cancer patients.
https://doi.org/10.1200/jco.2023.41.16_suppl.5590
New horizons for platinum-resistant ovarian cancer: insights from the 2023 American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) Annual Meetings
https://doi.org/10.1136/ijgc-2023-004927
Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model
https://doi.org/10.1136/jitc-2022-006509
nct03449108 at ClinicalTrials.govDocuments that mention this clinical trial
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
https://doi.org/10.1136/jitc-2021-003499
Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms
https://doi.org/10.1136/jitc-2025-013285
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
Specific recognition of an <i>FGFR2</i> fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma
https://doi.org/10.1136/jitc-2022-006303
Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response
https://doi.org/10.1136/jitc-2025-014644
Utilization of primary tumor samples for cancer neoantigen discovery
https://doi.org/10.1136/jitc-2024-010993
Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes
https://doi.org/10.1136/jitc-2023-008645
Deregulation of HLA-I in cancer and its central importance for immunotherapy
https://doi.org/10.1136/jitc-2021-002899
Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing
https://doi.org/10.1136/jitc-2021-002595
1216 Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers
https://doi.org/10.1136/jitc-2023-sitc2023.1216
184 Adoptive T cell therapies targeting common p53 neoantigens in human solid cancers
https://doi.org/10.1136/jitc-2021-sitc2021.184
nct02498912 at ClinicalTrials.govDocuments that mention this clinical trial
1338 Multi-cohort phase II study of autologous centrally manufactured tumor infiltrating lymphocytes
https://doi.org/10.1136/jitc-2025-sitc2025.1338
Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms
https://doi.org/10.1136/jitc-2025-013285
CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling
https://doi.org/10.1136/jitc-2021-003750
nct01567891 at ClinicalTrials.govDocuments that mention this clinical trial
Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms
https://doi.org/10.1136/jitc-2025-013285
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine
https://doi.org/10.1016/j.ygyno.2015.12.030
Immunological configuration of ovarian carcinoma: features and impact on disease outcome
https://doi.org/10.1136/jitc-2021-002873
Documents that mention this clinical trial
Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms
https://doi.org/10.1136/jitc-2025-013285
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine
https://doi.org/10.1016/j.ygyno.2015.12.030
Immunological configuration of ovarian carcinoma: features and impact on disease outcome
https://doi.org/10.1136/jitc-2021-002873
-
Funding
Funding for this research was provided by:
National Cancer Institute (2P50CA159981-07A1)
Roswell Park Alliance Foundation (N/A)
Ovarian Cancer Research Alliance (ECIG-2023-3-1005)
- License Information
